Gut Microbiota Emerges as Key Therapeutic Target for Osteoporosis Through Novel Gut-Bone Axis
核心洞察
Gut microbiota dysbiosis significantly contributes to osteoporosis (搜索) pathogenesis through disrupted immune responses, inflammatory cascades, and endocrine signaling pathways that promote bone loss.
Short-chain fatty acids (搜索) and beneficial bacteria like Lactobacillus and Bifidobacterium demonstrate protective effects against osteoporosis (搜索) by enhancing bone formation and suppressing osteoclast activity.
Microbiota-targeted interventions including probiotics, fecal microbiota transplantation, and dietary modifications show promising therapeutic potential for osteoporosis (搜索) management through gut-bone axis modulation.
Osteoporosis (搜索) affects over 200 million people worldwide, representing a major healthcare challenge as populations age. While traditional treatments focus on bone-targeting medications, emerging research reveals that the gut microbiota plays a crucial role in bone health through a sophisticated communication network termed the "gut-bone axis."
Gut Microbiota Dysbiosis Drives Bone Loss
Recent studies demonstrate that patients with osteoporosis (搜索) exhibit pronounced gut microbiota dysbiosis characterized by markedly reduced microbial community diversity. Osteoporotic individuals show elevated abundances of pathogenic bacteria including Bacteroidetes, Bacteroides, and Eisenbergiella, alongside increased Clostridium, Lactobacillus, and Eggerthella species.
Conversely, beneficial bacteria demonstrate reduced abundance in osteoporotic patients. Chen et al. identified substantial reductions in lactobacilli and butyrate-producing bacterial populations, despite paradoxically elevated concentrations of osteogenic metabolites derived from Lactobacillus acidophilus, L. rhamnosus, and butyrate-producing species.
Multiple Pathways Link Gut to Bone Health
The gut-bone axis operates through three primary mechanisms: direct metabolite effects, immune system modulation, and endocrine pathway regulation.
Direct Metabolite Effects
Short-chain fatty acids (搜索) (SCFAs), the principal products of dietary fiber fermentation by intestinal microbiota, directly influence bone metabolism. SCFAs activate G protein-coupled receptors and regulate key pathways including Wnt/β-catenin and RANKL (搜索)/RANK/OPG signaling. Butyrate promotes stromal cell osteogenic differentiation and mineralization through Wnt signaling (搜索) pathway activation, while propionate (搜索) and butyrate inhibit osteoclastogenesis through TNF receptor-associated factor 6 downregulation.
Tryptophan metabolites, including indole-acrylic acid and indole-3-propionic acid, achieve specific activation of the aryl hydrocarbon receptor (搜索), directly inhibiting osteoclast differentiation and promoting osteogenesis-related gene expression.
Immune System Modulation
Gut microbiota critically influence bone health through immune cell regulation. The balance between regulatory T cells (搜索) (Treg) and Th17 cells (搜索) is essential for maintaining bone homeostasis. Th17 cells drive osteoclastogenesis via RANKL (搜索)-dependent pathways, while Treg cells suppress osteoclast differentiation through cytotoxic T-lymphocyte-associated protein 4 signaling and promote osteoblast maturation.
SCFAs induce naïve CD4+ T cell differentiation toward regulatory Tregs, with probiotics such as Lactobacillus rhamnosus GG conferring bone protection via the SCFAs-Tregs-bone metabolism axis. Tryptophan metabolism enhances M2 macrophages and promotes IL-10 diffusion from intestinal lamina propria to bone marrow, significantly promoting osteogenesis.
Endocrine Pathway Regulation
Gut microbiota regulate skeletal homeostasis through bioactive compound production, influencing endocrine networks governing bone metabolism. Intestinal β-glucuronidase-yielding bacteria catabolize metabolized estrogen into deconjugated active forms, reabsorbing it through enterohepatic circulation. The serum estrogen then inhibits osteoclast differentiation through RANKL (搜索)/OPG signaling.
Enterochromaffin cells deliver serotonin, which exerts complex physiological effects on bone remodeling. However, elevated serotonin levels may lead to increased osteoclast activity and bone resorption, contributing to osteoporosis (搜索) development.
Therapeutic Interventions Show Promise
Multiple microbiota-targeted interventions demonstrate efficacy in preventing and treating osteoporosis (搜索) through gut-bone axis modulation.
Probiotic Interventions
Clinical trials reveal that specific probiotic strains effectively prevent osteoporotic progression. Bifidobacterium bifidum FL228.1 and Bifidobacterium animalis subsp. lactis F1-7 increase beneficial bacteria abundance while inhibiting pathogenic colonization, optimizing intestinal barrier integrity and improving bone health indices including bone mineral density and trabecular volume.
Lactobacillus rhamnosus GG strengthens bone microstructure by adjusting Firmicutes/Bacteroidetes ratios, maintaining Th17/Treg balance, and upregulating levels of glucagon-like peptide-2 receptor and bone formation markers.
Fecal Microbiota Transplantation
FMT represents a novel therapeutic approach that reconstructs gut microecological balance through healthy donor microbiota transfer. Studies demonstrate that FMT influences bone metabolism through microbiota compositional regulation, intestinal barrier improvement, and immune system modulation. However, clinical implementation faces challenges including safety concerns, donor screening requirements, and protocol standardization needs.
Dietary Interventions
Prebiotic supplementation shows significant bone health benefits. Oligofructose significantly increases SCFA content and bone mineral content, density, and trabecular volume in vertebral bodies through osteoblast and osteocyte gene expression independent of Treg cells. Konjac oligosaccharides increase bone trabeculae number by 134.2% and bone bending stiffness by 103.1% in ovariectomized rats.
Clinical Translation Challenges
Despite promising preclinical results, clinical translation faces several obstacles. Existing clinical trials feature limited sample sizes, brief follow-up periods, and considerable heterogeneity in probiotic strains and dosing regimens. Large-scale, multicenter, long-term randomized controlled trials are urgently needed to assess microbiota-targeted therapy effects on bone mineral density and fracture incidence.
The U.S. Food and Drug Administration issued safety alerts in 2023 highlighting FMT-associated severe infections, emphasizing the need for stringent screening and quality control protocols. Elderly individuals, representing the primary osteoporosis (搜索) population, exhibit increased susceptibility to FMT-associated adverse events due to age-related immune function decline.
Future Directions
The gut-bone axis concept extends beyond simple gut-bone interactions to encompass broader biological networks. Researchers propose "gut-bone axis plus X" frameworks incorporating brain-gut-bone, gut-liver-bone, and gut-bone-tumor axes, providing comprehensive approaches to osteoporosis (搜索) management.
Innovative therapeutic approaches include nanomedicine applications, with propolis nanoemulsions and gold nanospheres demonstrating anti-osteoporotic effects through gut-bone axis modulation. Extracellular vesicle engineering represents another promising frontier, with milk-derived and engineered bacterial extracellular vesicles showing efficacy in promoting beneficial bacterial colonization and inhibiting osteoclast differentiation.
The gut-bone axis represents a paradigm shift in osteoporosis (搜索) understanding and treatment, offering novel therapeutic targets beyond traditional bone-focused interventions. As research advances, microbiota-targeted therapies may provide personalized, effective approaches to preventing and treating this debilitating condition affecting millions worldwide.